Tianeptine.

5-HTP is the immediate precursor of serotonin and raises central serotonin availability, while tianeptine modulates the same serotonergic and glutamatergic circuits. Two inputs to one pathway are additive and the pairing needs care.

This is the same precursor entering serotonin synthesis one step ahead of the decarboxylase. Combined with an agent already acting on serotonergic transmission the effect on that pathway compounds.

Tryptophan feeds the hydroxylase step upstream of serotonin, raising the substrate pool for the same transmitter system tianeptine acts on. The additive load on one pathway is the reason the pairing needs care.

Dietary tryptophan is the entry point for serotonin synthesis and raises availability of the transmitter whose signalling tianeptine already modulates. Two inputs into one pathway act in the same direction.

St John's wort raises serotonergic tone and induces CYP3A4 and P-glycoprotein, so it pushes the same pathway while changing how co-administered compounds are cleared. Both directions of that interaction are well documented.

SAM-e supplies methyl groups used in monoamine synthesis and breakdown and independently raises monoaminergic tone. Alongside an agent already modulating those circuits the effects run in the same direction.

Two agents that each lower arousal, taken together, lower it further. The mu-opioid activity of tianeptine is the part that matters here and it is why this compound behaves unlike a conventional serotonergic antidepressant. Anyone combining them should regard the sedation as additive rather than assuming melatonin is inert on top.

GABAergic and opioidergic sedation are separate mechanisms that sum clinically. This is the standard pharmacological caution applied to any centrally sedating botanical taken alongside an opioid-active compound. No retrieved study tests the specific pair, and the caution does not need one.

The combination increases total central depressant load. Effect size for passionflower alone is modest in the human literature, so the practical concern is cumulative rather than dramatic. Flagged because the direction is predictable even without a combination study.

Magnolia bark extracts are taken for calming and sleep, which is the same direction of effect. Combined with an opioid-active compound the depressant effects sum. The interaction is inferred from each agent's known receptor activity, not measured together.

The calming effect of theanine is mild and not sedating in the way a GABA-A modulator is. Additive drowsiness is plausible rather than established. Included because the direction is consistent and someone stacking calm-focused ingredients should see it named.

How much orally administered GABA reaches the central nervous system is genuinely contested. Peripheral effects on the enteric nervous system and on heart rate variability are better supported than central ones. The additive concern here is real but smaller than for a lipophilic GABA-A modulator.

Ashwagandha's effect on subjective stress and sleep runs partly through GABA-A modulation. Combined with a mu-opioid agonist the sedative direction is shared. The pair has not been studied together and the flag rests on each agent's own pharmacology.

Rhodiola raises subjective alertness in fatigue studies, which is the opposite direction from mu-opioid sedation. That does not make it a corrective; opposing arousal effects can mask each other without cancelling the underlying pharmacology. Anyone using both should not read restored alertness as absence of the opioid effect.

Precursor loading raises catecholamine synthesis capacity under conditions of high turnover. It does not counteract mu-opioid activity. The pairing is common in nootropic stacking and is included so the distinction between the two systems is on record.